Enovis Posts Mixed 2025 Results Amid Goodwill Impairment
Event summary
- Enovis reported full-year 2025 sales growth of 7% on a reported basis and 6% organically, with Reconstructive sales up 10% and Prevention & Recovery up 4%.
- Fourth-quarter 2025 net sales grew 3% on a reported basis and 2% organically, with Reconstructive up 7% and Prevention & Recovery flat.
- The company recorded a full-year net loss of $1.18 billion, including a $1.05 billion goodwill impairment charge.
- Enovis expects 2026 revenue of $2.31-2.37 billion, with 4-6% organic growth and adjusted EBITDA of $425-435 million.
The big picture
Enovis' 2025 results highlight continued commercial momentum in its Reconstructive segment, but the significant goodwill impairment underscores valuation pressures in the medical technology sector. The company's focus on operational efficiency and innovation will be critical as it navigates dynamic global markets and positions itself for sustainable growth. With a strategic outlook emphasizing commercial execution and financial discipline, Enovis aims to capitalize on its above-market organic growth trends.
What we're watching
- Integration Progress
- How Enovis will advance its second-year Lima integration priorities and sustain operational improvements.
- Market Conditions
- Whether Enovis can maintain commercial execution and financial discipline amid evolving macroeconomic conditions.
- Innovation Pipeline
- The pace at which Enovis can advance its innovation pipeline to drive durable, capital-efficient growth.
Related topics